|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:dateCreated |
2010-11-24
|
|
pubmed:abstractText |
Interferon is approved for adjuvant treatment of patients with stage IIb/III melanoma. The toxicity and uncertainty regarding survival benefits of interferon have qualified its acceptance, despite significant durable relapse prevention in a fraction of patients. Predictive biomarkers that would enable selection of patients for therapy would have a large impact upon clinical practice. Specific CTLA-4 polymorphisms have previously shown an association with response to CTLA-4 blockade in patients with metastatic melanoma and the development of autoimmunity.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1479-5876
|
|
pubmed:author |
pubmed-author:AtkinsMichael BMB,
pubmed-author:BuchbinderElizabethE,
pubmed-author:CastanaOuraniaO,
pubmed-author:DafniUraniaU,
pubmed-author:FountzilasGeorgeG,
pubmed-author:GogasHelenH,
pubmed-author:KirkwoodJohn MJM,
pubmed-author:KoonHenryH,
pubmed-author:MarkopoulosChristosC,
pubmed-author:MetaxasYannisY,
pubmed-author:PanagiotouPetrosP,
pubmed-author:PectasidesEiriniE,
pubmed-author:PolyzosAristidisA,
pubmed-author:SkarlosPantelisP,
pubmed-author:Spyropoulou-VlachouMariaM,
pubmed-author:StratigosAlexandrosA,
pubmed-author:TsoutsosDimosthenisD
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
8
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
108
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:21044351-Antigens, CD,
pubmed-meshheading:21044351-Base Sequence,
pubmed-meshheading:21044351-CTLA-4 Antigen,
pubmed-meshheading:21044351-Case-Control Studies,
pubmed-meshheading:21044351-DNA Primers,
pubmed-meshheading:21044351-Gene Frequency,
pubmed-meshheading:21044351-Humans,
pubmed-meshheading:21044351-Interferons,
pubmed-meshheading:21044351-Melanoma,
pubmed-meshheading:21044351-Neoplasm Metastasis,
pubmed-meshheading:21044351-Polymerase Chain Reaction,
pubmed-meshheading:21044351-Polymorphism, Single Nucleotide,
pubmed-meshheading:21044351-Survival Analysis
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial.
|
|
pubmed:affiliation |
First Department of Medicine, University of Athens, Medical School, Athens, Greece. hgogas@hol.gr
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Research Support, N.I.H., Extramural
|
